Vertex Pharmaceuticals (VRTX) Cost of Revenue (2011 - 2026)

Vertex Pharmaceuticals' Cost of Revenue history runs 16 years deep, the most recent figure standing at $392.8 million for Q1 2026.

• In Q1 2026, Cost of Revenue rose 8.21% year-over-year to $392.8 million; the TTM figure through Mar 2026 stood at $1.7 billion (up 8.4% YoY), while the FY2025 annual figure was $1.7 billion, up 7.89% from the prior year.
• Cost of Revenue was $392.8 million for Q1 2026 at Vertex Pharmaceuticals, down from $466.0 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $466.0 million in Q4 2025 to a low of $245.8 million in Q1 2022.
• Historically, Cost of Revenue has averaged $348.1 million across 5 years, with a median of $363.0 million in 2025.
• The sharpest annual moves came in 2023 and 2025: Cost of Revenue increased 29.9% in 2023, then advanced 5.65% in 2025.
• A 5-year view of Cost of Revenue shows it stood at $283.3 million in 2022, then climbed by 29.9% to $368.0 million in 2023, then grew by 15.05% to $423.4 million in 2024, then gained by 10.06% to $466.0 million in 2025, then decreased by 15.71% to $392.8 million in 2026.
• The last three Cost of Revenue figures came in at $392.8 million (Q1 2026), $466.0 million (Q4 2025), and $414.8 million (Q3 2025), per Business Quant data.